Equities Analysts Set Expectations for AUTL FY2024 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL) – Research analysts at William Blair cut their FY2024 EPS estimates for shares of Autolus Therapeutics in a note issued to investors on Tuesday, November 12th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($1.09) per share for the year, down from their previous forecast of ($0.92). The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.84) per share. William Blair also issued estimates for Autolus Therapeutics’ Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.53) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter last year, the business posted ($0.26) EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $3.01 on Friday. The firm has a market capitalization of $800.94 million, a P/E ratio of -2.49 and a beta of 2.04. The company’s fifty day moving average price is $3.92 and its two-hundred day moving average price is $3.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. Autolus Therapeutics has a 12 month low of $2.98 and a 12 month high of $7.45.

Institutional Trading of Autolus Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH acquired a new position in Autolus Therapeutics during the 3rd quarter worth $708,000. Bellevue Group AG raised its stake in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares in the last quarter. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter worth about $51,000. FMR LLC grew its position in Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares in the last quarter. Finally, HealthInvest Partners AB increased its stake in Autolus Therapeutics by 95.6% during the 3rd quarter. HealthInvest Partners AB now owns 442,423 shares of the company’s stock valued at $1,606,000 after buying an additional 216,278 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.